MLH1 promoter methylation is associated with a specific BRAF mutation (V600E) which is therefore used as an additional parameter for excluding patients from genetic testing since the tumor MSI in these cases is unlikely to result from a germline MMR gene inactivation [18, 19]. This evidence concerns the gene MLH1 and neoplasm.